The role of BRCA1 in the cellular response to chemotherapy

Journal of the National Cancer Institute

Volumn 96, Issue 22, 2004, Pages 1659-1668

  Kennedy, Richard D ^a   Quinn, Jennifer E ^a   Mullan, Paul B ^a   Johnston, Patrick G ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINCA ALKALOID;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL ACTIVITY; CELL CYCLE; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; FANCONI ANEMIA; FEMALE; GENE MUTATION; GERM LINE; HUMAN; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA TRANSCRIPTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENETIC MARKERS; GERM-LINE MUTATION; HUMANS; MITOTIC SPINDLE APPARATUS; MUTAGENS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UBIQUITINS;

EID: 9744263911     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh312     Document Type: Review

References (115)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
3. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001;92:54-60.
4. Taylor J, Lymboura M, Pace PE, A'Hern RP, Desai AJ, Shousha S, et al. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 1998;79:334-42.
5. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer 1999; 80:823-6.
6. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
7. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
8. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-23.
9. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-14.
10. Baum M. Tamoxifen - the treatment of choice. Why look for alternatives? Br J Cancer 1998;78 Suppl 4:1-4.
11. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8:811-6.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
13. Thor AD, Berry DA, Budman DR, Muss HB, Kure T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
14. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90: 1361-70.
15. Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002;38:535-42.
16. Matthew V, Yee H, Symmans WF, Formenti S, Wratz K, Shapiro R, et al. HER status predicts response to preoperative paclitaxel in patients with breast cancer. Proc ASCO 1999;18:A394.
17. Chakravarthy B, Pietenpol JA. Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol 2003;30:23-36.
18. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9:183-95.
19. Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, et al. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 2000;20:4793-9.
20. Johnson KR, Fan W. Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002;22:3197-204.
21. Rantanen V, Engblom P, Raitanen M, Hietanen S, Haarala M, Grenman S, et al. Mutations of TP53 do not correlate with the sensitivity to paclitaxel-a study using 27 gynaecological cancer cell lines. Eur J Cancer 2002;38:1783-91.
22. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001;14:165-71.
23. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 2001;92:738-47.
24. Munster PN, Norton L. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res 2001;3:361-4.
25. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339: 974-84.
26. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-15.
27. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003;89 Suppl 3:S9-15.
28. McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89 Suppl 3:S3-8.
29. McGuire WP, 3rd. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 2003;21:133-5.
30. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-6.
31. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-10.
32. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 1997;16:298-302.
33. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001;28:266-71.
34. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
35. McHugh PJ, Sones WR, Hartley JA. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 2000;20:3425-33.
36. Tercero JA, Diffley JF, Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. Nature 2001;412: 553-7.
37. Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS, Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J 1999;18:1397-406.
38. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
39. Zdraveski ZZ, Mello JA, Marinus MG, Essigmann JM. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 2000; 7:39-50.
40. D'Andrea AD, Haseltine WA. Sequence specific cleavage of DNA by the antitumor antibiotics neocarzinostatin and bleomycin. Proc Natl Acad Sci U S A 1978;75:3608-12.
41. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
42. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
43. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
44. MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002;22:4280-92.
45. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999;285:747-50.
46. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
47. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000;10:144-50.
48. Gilmore PM, Quinn JE, Mullan PB, Andrews HN, McCabe N, Carty M, et al. Role played by BRCA1 in regulating the cellular response to stress. Biochem Soc Trans 2003;31:257-62.
49. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-50.
50. Chu G. Double strand break repair. J Biol Chem 1997;272:24097-100.
51. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-8.
52. Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, et al. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 2002;21:1401-10.
53. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem 2002;277:28641-7.
54. McHugh PJ, Gill RD, Waters R, Hartley JA. Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. Nucleic Acids Res 1999;27:3259-66.
55. Dunkern TR, Fritz G, Kaina B. Ultraviolet light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells via Bcl-2 decline and caspase-3/-8 activation. Oncogene 2001;20:6026-38.
56. Wood R. Nucleotide excision repair in mammalian cells. J Biol Chem 1997;19:23465-8.
57. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000;60:5548-52.
58. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinwn(II). Cancer Res 1998;58:1120-3.
59. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
60. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88: 1285-91.
61. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-606.
62. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 1999;96:11364-9.
63. Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 1999;38:6204-12.
64. Bregman DB, Halaban R, van Gool AJ, Henning KA, Friedberg EC, Warren SL. UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. Proc Natl Acad Sci U S A 1996;93:11586-90.
65. Ratner JN, Balasubramanian B, Corden J, Warren SL, Bregman DB. Ultraviolet radiation-induced ubiquitination and proteasomal degradation of the large subunit of RNA polymerase II. Implications for transcription-coupled DNA repair. J Biol Chem 1998;273:5184-9.
66. Lee KB, Wang D, Lippard SJ, Sharp PA. Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro. Proc Natl Acad Sci U S A 2002;99:4239-44.
67. Li Z, Xiao W, McCormick JJ, Maher VM. Identification of a protein essential for a major pathway used by human cells to avoid UV- induced DNA damage. Proc Natl Acad Sci U S A 2002;99:4459-64.
68. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998;19:254-6.
69. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002;32:180-4.
70. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-9.
71. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21:3445-50.
72. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002;62:4588-91.
73. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-31.
74. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003;300:1542-8.
75. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 2001; 276:17276-80.
76. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
77. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-4.
78. Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000;14:2989-3002.
79. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998;95:2302-6.
80. Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2002;21:3199-206.
81. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997;389:187-90.
82. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 1999;96:3706-11.
83. MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000;275: 2777-85.
84. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-59.
85. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 2003;22:8952-5.
86. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708-18.
87. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
88. Folias A, Matkovic M, Bruun D, Reid S, Hejna J, Grompe M, et al. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum Mol Genet 2002;11:2591-7.
89. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 2004;23:1178-87.
90. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
91. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001;20:4704-16.
92. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
93. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-101.
94. Wassmann K, Benezra R. Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 2001;11:83-90.
95. Lotti LV, Ottini L, D'Amico C, Gradini R, Cama A, Belleudi F, et al. Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 2002;35:193-203.
96. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res 2001;61:7713-8.
97. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3: 389-95.
98. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004;23:596-604.
99. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-86.
100. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000;275:33487-96.
101. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
102. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003;22:1169-73.
103. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002; 20:845-53.
104. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003;22:2396-404.
105. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
106. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
107. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-10.
108. Delaloge S PP, Kloos I, et al. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts [abstract 120]. Nice (France): Program and abstracts of the 27th Congress of the European Society for Medical Oncology 2002.
109. Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003;97:527-36.
110. Egawa C, Motomura K, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003;78:45-50.
111. Quinn JE, Kennedy RD, Mullan PB, Gilmore PG, Johnston PG, Harkin DP. BRCA1 acts as a differential modulator of sensitivity to chemotherapeutic agents. Clin Cancer Res 2003;63:6221-8.
112. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
113. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000;27:3-7.
114. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001;95:255-9.
115. Crown J. Docetaxel: overview of an active drug for breast cancer. Oncologist 2001;6 Suppl 3:1-4.